Preheparin serum lipoprotein lipase mass might be a biomarker of metabolic syndrome.

@article{Saiki2007PreheparinSL,
  title={Preheparin serum lipoprotein lipase mass might be a biomarker of metabolic syndrome.},
  author={Atsuhito Saiki and Tomokazu Oyama and Kei Endo and Mariko Ebisuno and Masahiro Ohira and Nobukiyo Koide and Takeyoshi Murano and Yoh Miyashita and Kohji Shirai},
  journal={Diabetes research and clinical practice},
  year={2007},
  volume={76 1},
  pages={
          93-101
        }
}
Lipoprotein lipase mass in preheparin serum (preheparin LPL mass) is assumed to reflect some of the LPL production in the whole body and insulin sensitivity. While metabolic syndrome is a common underlying condition for cardiovascular diseases, biological marker of this syndrome has not been fully established. To clarify the characteristics of preheparin LPL mass in metabolic syndrome, 362 Japanese subjects were studied to examine the relationship between symptoms of metabolic syndrome and… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 38 CITATIONS

Maternal obesity is associated with the formation of small dense LDL and hypoadiponectinemia in the third trimester.

  • The Journal of clinical endocrinology and metabolism
  • 2013
VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Serum lipoprotein lipase mass: clinical significance of its measurement.

  • Clinica chimica acta; international journal of clinical chemistry
  • 2007
VIEW 2 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED